iCAD, Inc. (NASDAQ:ICAD) Given Average Rating of “Moderate Buy” by Analysts

Shares of iCAD, Inc. (NASDAQ:ICADGet Rating) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $8.60.

ICAD has been the topic of a number of research reports. Craig Hallum lowered their price objective on iCAD to $6.00 in a research note on Monday, August 15th. BTIG Research lowered their price objective on iCAD to $6.00 in a research note on Monday, August 15th. JMP Securities lowered their price objective on iCAD from $13.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, September 1st. Finally, Lake Street Capital lowered their price objective on iCAD from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, August 11th.

iCAD Price Performance

NASDAQ ICAD opened at $2.35 on Friday. The stock has a market capitalization of $59.53 million, a price-to-earnings ratio of -4.52 and a beta of 1.13. iCAD has a one year low of $2.00 and a one year high of $12.60. The business’s fifty day moving average is $3.24 and its 200-day moving average is $3.68.

Insider Buying and Selling at iCAD

In other iCAD news, CTO Jonathan Go sold 38,960 shares of iCAD stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $2.74, for a total transaction of $106,750.40. Following the completion of the transaction, the chief technology officer now owns 188,725 shares of the company’s stock, valued at approximately $517,106.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its holdings in shares of iCAD by 26.9% during the first quarter. Rhumbline Advisers now owns 19,635 shares of the technology company’s stock worth $88,000 after purchasing an additional 4,159 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of iCAD by 7.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 60,038 shares of the technology company’s stock worth $268,000 after purchasing an additional 4,253 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in iCAD by 4.8% in the first quarter. Essex Investment Management Co. LLC now owns 122,011 shares of the technology company’s stock worth $544,000 after buying an additional 5,639 shares in the last quarter. Raymond James & Associates boosted its stake in iCAD by 62.1% in the first quarter. Raymond James & Associates now owns 21,750 shares of the technology company’s stock worth $97,000 after buying an additional 8,331 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in iCAD in the second quarter worth approximately $46,000. Hedge funds and other institutional investors own 52.68% of the company’s stock.

About iCAD

(Get Rating)

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.

Read More

Analyst Recommendations for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.